Colorectal Cancer | Specialty

The OncLive Colorectal Cancer condition center page is a comprehensive resource for clinical news and expert insights on colorectal cancer treatment and management, with a focus on novel therapeutic strategies including checkpoint inhibitors and TKIs across lines of therapy. This page features news articles, interviews in written and video format, and podcasts that focus on unmet needs, treatment advances, and ongoing research in colorectal cancer.

Managing Toxicities Associated With Regorafenib

August 8th 2014

Case Studies in Advanced Colorectal Cancer

August 8th 2014

Optimal Dosing of Regorafenib in CRC

August 8th 2014

Treatment Options for Advanced CRC

August 8th 2014

New Tactics Needed: Aspirin Studies in Colon Cancer Illustrate Shortcomings of Phase III Trial Orthodoxy

August 5th 2014

There is a tension in the air these days when it comes to the manner in which evidence-based oncology research should be conducted in this revolutionary era, and that tension is evident on the pages of peer-reviewed articles describing novel findings in clinical molecular oncology, in editorials discussing these studies, and in commentaries related to future approaches to discovery.

Dr. Bekaii-Saab Discusses an Analysis of Bevacizumab or Cetuximab for CRC

July 24th 2014

Tanios Bekaii-Saab, MD, discusses an analysis of two targeted drugs for the treatment of patients with colorectal cancer (CRC).

Final Thoughts on Optimizing the Treatment of mCRC

July 23rd 2014

TAS-102 in Refractory mCRC

July 23rd 2014

Optimizing Treatment With Regorafenib in mCRC

July 23rd 2014

BRAF-Mutated Colorectal Cancer

July 23rd 2014

Second-Line Treatment Options in mCRC

July 23rd 2014

Future Analyses From the 80405 mCRC Trial

July 23rd 2014

Conducting Extended RAS Testing in CRC

July 23rd 2014

Extended RAS Testing in Metastatic CRC

July 23rd 2014

CALGB 80405 Trial Results in mCRC

July 23rd 2014

Introduction: Bevacizumab Versus Cetuximab in mCRC

July 23rd 2014

Dr. Hoff on Delivering Chemotherapy Until Progression Versus Complete Stop in mCRC

July 22nd 2014

Paulo Marcelo Hoff, MD, PhD, FACP, University of SÃ£o Paulo, Brazil, discusses a meta-analysis of randomized trials that examined the effect of chemotherapy delivered until progression versus complete stop on the overall survival of patients with metastatic colorectal cancer (mCRC).

Dr. Fakih on Advances in Liver-Directed Therapies in CRC

July 3rd 2014

Marwan G. Fakih, MD, professor, director, Gastrointestinal Medical Oncology, City of Hope, discusses recent advances in liver-directed therapies in colorectal cancer (CRC).

Dr. Arnold on a Phase III Trial Examining Options for Maintenance Therapy in mCRC

July 2nd 2014

Dirk Arnold, MD, director, Department of Medical Oncology, Tumour Biology Centre, Freiburg, Germany, discusses a phase III trial looking at options for maintenance therapy for metastatic colorectal cancer (mCRC).

Dr. Yoshino Discusses the Safety Profile of TAS-102

June 30th 2014

Takayuki Yoshino, MD, medical oncologist, National Cancer Center Hospital East, Chiba, Japan, discusses the safety profile of TAS-102 as seen in a phase III study of the agent versus placebo, with best supportive care, in patients with metastatic colorectal cancer (mCRC) refractory to standard therapies.